Immunotherapies for non-small-cell lung cancer and mesothelioma

The Lancet Oncology

Volumn 13, Issue 7, 2012, Pages

  Thomas, Anish ^a   Hassan, Raffit ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; ANTINEOPLASTIC AGENT; BELAGENPUMATUCEL L; CADI 05; CANCER VACCINE; CARBOPLATIN; CISPLATIN; CRS 207; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; EMEPEPIMUT S; GEMCITABINE; IPILIMUMAB; MELANOMA ANTIGEN 3 VACCINE; MITOMYCIN; PACLITAXEL; PEPTIDE VACCINE; PLACEBO; SRL 172; TALACTOFERRIN; TICILIMUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VINBLASTINE; WT1 DERIVATIVE PEPTIDE VACCINE;

ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FLU LIKE SYNDROME; HUMAN; IMMUNE DEFICIENCY; IMMUNOPHARMACOLOGY; INFECTION; INJECTION SITE REACTION; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; SOLID TUMOR; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; CTLA-4 ANTIGEN; DENDRITIC CELLS; GPI-LINKED PROTEINS; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MESOTHELIOMA; NEOPLASM PROTEINS; TOLL-LIKE RECEPTORS; WT1 PROTEINS;

EID: 84863113633     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70126-2     Document Type: Review

References (95)

1. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007, 2:706-714.
2. Jemal A, Siegel R, Xu J, Ward E Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
3. Weill H Changing trends in US mesothelioma incidence. Occup Environ Med 2004, 61:438-441.
4. Robinson BW Advances in malignant mesothelioma. N Engl J Med 2005, 353:1591-1603.
5. Schiller JH, Harrington D, Belani C, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
6. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
7. Rosenberg SA, Yang JC, Restifo NP Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915.
8. Klebanoff CA, Acquavella N, Yu Z, Restifo NP Therapeutic cancer vaccines: are we there yet?. Immunol Rev 2011, 239:27-44.
9. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
10. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
11. Leigh RA, Webster I Lymphocytic infiltration of pleural mesothelioma and its significance for survival. S Afr Med J 1982, 61:1007-1009.
12. Robinson C, Robinson BW, Lake RA Sera from patients with mesothelioma can contain autoantibodies. Lung Cancer 1998, 20:175-184.
13. Robinson BW, Robinson C, Lake RA Localised spontaneous regression in mesothelioma-possible immunological mechanism. Lung Cancer 2001, 32:197-201.
14. Ho M, Hassan R, Zhang J, et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 2005, 11:3814-3820.
15. Nakamura Y, Noguchi Y, Satoh E, et al. Spontaneous remission of a non-small cell lung cancer possibly caused by anti-NY-ESO-1 immunity. Lung Cancer 2009, 65:119-122.
16. Tsuji T, Altorki NK, Ritter G, Old LJ, Gnjatic S Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination. J Immunol 2009, 183:4800-4808.
17. Fischer JR, Darjes H, Lahm H, Schindel M, Drings P, Krammer PH Constitutive secretion of bioactive transforming growth factor β 1 by small cell lung cancer cell lines. Eur J Cancer 1994, 30:2125-2129.
18. Jakowlew SB, Mathias A, Chung P, Moody TW Expression of transforming growth factor β ligand and receptor messenger RNAs in lung cancer cell lines. Cell Growth Differ 1995, 6:465-476.
19. Huang M, Sharma S, Mao JT, Dubinett SM Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 1996, 157:5512-5520.
20. Dohadwala M, Luo J, Zhu L, et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 2001, 276:20809-20812.
21. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002, 168:4272-4276.
22. Batra RK, Lin Y, Sharma S, et al. Non-small cell lung cancer-derived soluble mediators enhance apoptosis in activated T lymphocytes through and I κB kinase-dependent mechanism. Cancer Res 2003, 63:642-646.
23. Atanackovic D, Block A, de Weerth A, Faltz C, Hossfeld D, Hegewisch-Becker S Characterization of effusion-infiltrating T cells: benign versus malignant effusions. Clin Cancer Res 2004, 10:2600-2610.
24. DeLong P, Carroll RG, Henry AC, et al. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther 2005, 4:342-346.
25. Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 2006, 27:1086-1095.
26. Meloni F, Morosini M, Solari N, et al. FoxP3 expressing CD4+CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 2006, 67:1-12.
27. North S, Butts C Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Exp Rev Vaccines 2005, 4:249-257.
28. Sangha R, Butts C L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 2007, 13:4652-4654.
29. Reddish MA, MacLean GD, Poppema S, Berg A, Longenecker BM Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother 1996, 42:303-339.
30. Li Y, Liu D, Chen D, Kharbanda S, Kufe D Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 2003, 22:6107-6110.
31. Yin L, Li Y, Ren J, Kuwahara H, Kufe D Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem 2003, 278:35458-35464.
32. Ren J, Agata N, Chen D, et al. Human MUC1 carcinoma-associated protein confers resistance genotoxic anticancer agents. Cancer Cell 2004, 5:163-175.
33. Rahn JJ, Chow JW, Horne GJ, et al. MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin Exp Metastasis 2005, 22:475-483.
34. Samuel J, Budzynski WA, Reddish MA, et al. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine. Int J Cancer 1998, 75:295-302.
35. Palmer M, Parker J, Modi S, et al. Phase I study of BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB-IV non-small cell lung cancer. Clin Lung Cancer 2001, 3:49-57.
36. Butts C, Murray RN, Smith CJ, et al. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. Clin Lung Cancer 2010, 11:391-395.
37. Ohyanagi F, Horai T, Sekine I, et al. Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a phase I/II study. Jpn J Clin Oncol 2011, 41:718-722.
38. Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005, 23:6674-6681.
39. Butts C, Maksymiuk A, Goss G, et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 2011, 137:1337-1342.
40. Butts C, Anderson H, Maksymiuk A, et al. Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2009, 27(suppl 15). abstr 3055.
41. Blobe GC, Schiemann WP, Lodish HF Role of transforming growth factor β in human disease. N Engl J Med 2000, 342:1350-1358.
42. Ikushima H, Miyazono K TGFβ signalling: a complex web in cancer progression. Nat Rev Cancer 2010, 10:415-424.
43. Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS Plasma transforming growth factor-β1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 1999, 86:1712-1719.
44. Fakhrai H, Dorigo O, Shawler DL, et al. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci USA 1996, 93:2909-2914.
45. Marzo AL, Fitzpatrick DR, Robinson BW, et al. Antisense oligonucleotides specific for transforming growth factor β2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 1997, 57:3200-3207.
46. Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor β-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006, 24:4721-4730.
47. Nemunaitis J, Nemunaitis M, Senzer N, et al. Phase II trial of belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer patients. Cancer Gene Ther 2009, 16:620-624.
48. Caballero OL, Chen YT Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009, 100:2014-2021.
49. Jang SJ, Soria JC, Wang L, et al. Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis. Cancer Res 2001, 61:7959-7963.
50. Bolli M, Kocher T, Adamina M, et al. Tissue microarray evaluation of melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg 2002, 236:785-793.
51. Gure AO, Chua R, Williamson B, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005, 11:8055-8062.
52. Atanackovic D, Altorki NK, Stockert E, et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 2004, 172:3289-3296.
53. Atanackovic D, Altorki NK, Cao Y, et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA 2008, 105:1650-1655.
54. Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 2007, 25(suppl 18). abstr 7554.
55. Vansteenkiste J, Zielinski M, Dahabreh IJ, et al. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 2008, 26(suppl 18). abstr 7501.
56. Alegre ML, Frauwirth KA, Thompson CB T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001, 1:220-228.
57. Lynch TJ, Bondarenko IN, Luft A, et al. Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(suppl 15). abstr 7531.
58. Zatloukal P, Heo DS, Park K, et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009, 27(suppl 15). abstr 8071.
59. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010, 28:3167-3175.
60. Akira S, Takeda K Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
61. Holtick U, Scheulen ME, von Bergwelt-Baildon MS, Weihrauch MR Toll-like receptor 9 agonists as cancer therapeutics. Expert Opin Investig Drugs 2011, 20:361-372.
62. Droemann D, Albrecht D, Gerdes J, et al. Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res 2005, 6:1.
63. Krieg AM Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006, 5:471-484.
64. Weeratna RD, Bourne LL, Sullivan SM, et al. Combination of a new TLR9 agonist immunomodulator (CpG 7909) and paclitaxel for treatment of metastatic Lewis lung carcinoma (LLC). J Clin Oncol 2004, 22(suppl 14). abstr 7346.
65. Vicari AP, Luu R, Zhang N, et al. Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother 2009, 58:615-628.
66. Manegold C, Gravenor D, Woytowitz D, et al. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3979-3986.
67. Manegold C, van Zandwijk N, Szczesna A, et al. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2012, 23:72-77.
68. Hirsh V, Paz-Ares L, Boyer M, et al. Randomized phase III trial of paclitaxel/carboplatin with or without pf-3512676 (toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011, 29:2667-2674.
69. Grange JM, Bottasso O, Stanford CA, Stanford JL The use of mycobacterial adjuvant-based agents for immunotherapy of cancer. Vaccine 2008, 26:4984-4990.
70. O'Brien ME, Saini A, Smith IE, et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer 2000, 83:853-857.
71. O'Brien ME, Anderson H, Kaukel E, et al. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. Ann Oncol 2004, 15:906-914.
72. Stanford JL, Stanford CA, O'Brien ME, Grange JM Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer 2008, 44:224-227.
73. Khamar BM, Sur PK, Dastidar AG Poly-TLR agonist polyantigenic vaccine cadi-05 in advanced nonsmall cell lung cancer. Proc Am Assoc Cancer Res 2006, 47(suppl). abstr 2905.
74. Belani CP, Desai D, Khamar BM, et al. Open-label, randomized multicenter phase II clinical trial of a toll-like receptor-2 (TLR2) agonist mycobacterium w (Cadi-05) in combination with paclitaxel plus cisplatin versus paclitaxel plus cisplatin in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2011, 29(suppl). abstr 7501.
75. Spadaro M, Caorsi C, Ceruti P, et al. Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells. FASEB J 2008, 22:2747-2757.
76. Hayes TG, Digumarti R, Engelmeyer J, et al. Effect of oral talactoferrin (TLF) on levels of cytokines involved in the Th1-mediated immune response in clinical studies. J Clin Oncol 2008, 26(suppl 15). abstr 3080.
77. Hayes TG, Falchook GF, Varadhachary GR, et al. Phase I trial of oral talactoferrin alfa in refractory solid tumors. Invest New Drugs 2006, 24:233-240.
78. Digumarti R, Wang Y, Raman G, et al. A randomized, double-blind, placebo-controlled phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. J Thorac Oncol 2011, 6:1098-1103.
79. Parikh PM, Vaid A, Advani SH, et al. Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. J Clin Oncol 2011, 29:4129-4136.
80. Keilholz U, Menssen HD, Gaiger A, et al. Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia 2005, 19:1318-1323.
81. May RJ, Dao T, Pinilla-Ibarz J, et al. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res 2007, 13:4547-4555.
82. Krug LM, Dao T, Brown AB, et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother 2010, 59:1467-1479.
83. Krug LM, Tsao AS, Kass S, et al. Randomized, double-blinded, phase II trial of a WT1 peptide vaccine as adjuvant therapy in patients with malignant pleural mesothelioma (MPM). J Clin Oncol 2011, 29(suppl). abstr TPS139.
84. Banchereau J, Palucka AK Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005, 5:296-306.
85. Reinhard G, Märten A, Kiske SM, Feil F, Bieber T, Schmidt-Wolf IG Generation of dendritic cell-based vaccines for cancer therapy. Br J Cancer 2002, 86:1529-1533.
86. Hegmans JP, Hemmes A, Aerts JG, Hoogsteden HC, Lambrecht BN Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am J Respir Crit Care Med 2005, 171:1168-1177.
87. Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med 2010, 181:1383-1390.
88. Veltman JD, Lambers ME, van Nimwegen M, et al. Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity. J Biomed Biotechnol 2010, 2010:798467.
89. Brockstedt DG, Giedlin MA, Leong ML, et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci USA 2004, 101:13832-13837.
90. Chang K, Pastan I Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996, 93:136-140.
91. Hassan R, Bera T, Pastan I Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004, 10:3937-3942.
92. Le DT, Brockstedt D, Nir-Paz R, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase 1 studies of safety and immune induction. Clin Cancer Res 2012, 18:858-868.
93. Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010, 102:1388-1397.
94. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15:7412-7420.
95. Schlom J, Arlen PM, Gulley JL Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007, 13:3776-3782.